Reactivation of P53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

Current Cancer Drug Targets - United Arab Emirates
doi 10.2174/156800910791190229
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy

Cancer Research
Cancer ResearchOncology
2018English

Targeting P53-Mdm2-MDMX Loop for Cancer Therapy

Sub-Cellular Biochemistry
BiochemistryCancer ResearchCell BiologyMolecular Biology
2014English

Affinity-Based Screening of MDM2/MDMX–p53 Interaction Inhibitors by Chemical Array: Identification of Novel Peptidic Inhibitors

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2013English

Novel Thioredoxin Inhibitors for Breast Cancer Therapy

2002English

Novel Thioredoxin Inhibitors for Breast Cancer Therapy

2001English

Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach

Chemical Biology and Drug Design
BiochemistryOrganic ChemistryDrug DiscoveryMolecular MedicinePharmacology
2014English

P53 Mediated Death of Cells Overexpressing MDM2 by an Inhibitor of MDM2 Interaction With P53

Oncogene
Cancer ResearchGeneticsMolecular Biology
1999English

P53 Reactivation

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy